Despite mixed signals, Amgen's stock should experience a short-term positive impact due to a series of favorable updates including above-expectation revenue growth for Q2, significant progress in key pipeline advancements like AMG145, and strategic business development initiatives indicating a focused growth strategy. Moreover, raised full-year guidance underscores management's confidence in the company's trajectory.

[1]